Micro Labs USA Launches Two New Glaucoma Drugs

Source: Micro Labs USA

Micro Labs USA  is launching two products for the treatment of glaucoma in the United States: Dorzolamide 2% and Dorzolamide-Timolol 22.3-6.8 mg/mL.

Micro Labs USA said there are additional ophthalmic products under development as well, in various stages of FDA review, that Micro Labs USA plans to launch to address the growing needs for the US ophthalmic market.

Citing market research company IQVIA, usage of these two products in the US amounts to approximately $150 million in revenue, according to Micro Labs USA.

Related Content